Budget Impact Analysis of Ferric Derisomaltose for the Treatment of Iron-Deficiency in Malaysia
https://doi.org/10.47836/mjmhs.19.4.17
- Author:
Huey Yi Chong
1
;
June Wai Yee Choon
2
;
Wei Chern Ang
3
,
4
;
Kenneth Kwing Chin Lee
5
,
6
Author Information
1. School of Pharmacy, Monash University Malaysia, 45000 Bandar Sunway, Selangor, Malaysia
2. Pharmaceutical Association of Malaysia (PhAMA), 46300 Petaling Jaya, Selangor, Malaysia
3. Clinical Research Centre, Hospital Tuanku Fauziah, Ministry of Health Malaysia, 01000 Kangar, Perlis, Malaysia&
4. Department of Pharmacy, Hospital Tuanku Fauziah, Ministry of Health Malaysia, 01000 Kangar, Perlis, Malaysia
5. School of Pharmacy, Faculty of Health and Medical Sciences, Taylor&rsquo
6. s University, 47500 Subang Jaya, Selangor, Malaysia
- Publication Type:Journal Article
- Keywords:
Saccharated ferric oxide, Ferric derisomaltose, Cost savings, Iron deficiencies, Anaemia
- From:Malaysian Journal of Medicine and Health Sciences
2023;19(No.4):110-116
- CountryMalaysia
- Language:English
-
Abstract:
Introduction: Untreated iron deficiency (ID) can lead to severe anaemia, requiring blood transfusion, or increased
mortality risk. Globally intravenous (IV) iron is increasingly recognised as a recommended option for patients. This
study aims to evaluate the budget impact associated with introducing a new intravenous (IV) iron, ferric derisomaltose (Monofer® [IIM]) as one of the treatment options for the management of ID in the Ministry of Health Malaysia
(MOHM) setting. Methods: A 5-year budget impact model was developed from 2020 to 2024 for patients with ID
that require a high iron dose (≥500 mg), using the perspective of MOHM. The model was built with four external
medical specialists, each with experience and deep knowledge of ID management, to support estimations on the
future development of iron use in Malaysia. Results: Compared to the current market mix with the existing IV iron
products (i.e., iron sucrose and iron dextran), a cost-saving of MYR 53,910 could be achieved with the introduction
of IIM in 2020. The uptake of IIM into MOHM over five years is estimated to lead to an overall budget saving of MYR
11,837,524 over a 5-year time horizon. Conclusion: The use of IIM in place of the current IV iron products in MOHM
resulted in a significant cost saving by reducing the number of visits required to achieve the targeted iron dose and
the shorter IV infusion time with IIM.
- Full text:11.2023my1568.pdf
